122 related articles for article (PubMed ID: 25565775)
21. A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.
Zhou Z; Liao G; Mandal SS; Suryawanshi S; Guo Z
Chem Sci; 2015 Dec; 6(12):7112-7121. PubMed ID: 26918109
[TBL] [Abstract][Full Text] [Related]
22. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and immunological evaluation of N-acyl modified Tn analogues as anticancer vaccine candidates.
Song C; Sun S; Huo CX; Li Q; Zheng XJ; Tai G; Zhou Y; Ye XS
Bioorg Med Chem; 2016 Feb; 24(4):915-20. PubMed ID: 26787275
[TBL] [Abstract][Full Text] [Related]
24. Calix[4]arene decorated with four Tn antigen glycomimetic units and P3CS immunoadjuvant: synthesis, characterization, and anticancer immunological evaluation.
Geraci C; Consoli GM; Galante E; Bousquet E; Pappalardo M; Spadaro A
Bioconjug Chem; 2008 Mar; 19(3):751-8. PubMed ID: 18293897
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
26. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
27. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.
Keding SJ; Danishefsky SJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):11937-42. PubMed ID: 15280546
[TBL] [Abstract][Full Text] [Related]
28. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
[TBL] [Abstract][Full Text] [Related]
29. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
30. Augmenting the immunogenicity of carbohydrate tumor antigens.
Livingston PO
Semin Cancer Biol; 1995 Dec; 6(6):357-66. PubMed ID: 8938274
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and initial immunological evaluation of glycoconjugates based on saponin adjuvants and the Tn antigen.
Fuentes R; Aguinagalde L; Sacristán N; Fernández-Tejada A
Chem Commun (Camb); 2021 Oct; 57(86):11382-11385. PubMed ID: 34647563
[TBL] [Abstract][Full Text] [Related]
32. Influence of terminal residue on adjacent disaccharide immunogenicity.
Irazoqui FJ; Lopez PH; Mandel U; Nores GA
Mol Immunol; 2002 Mar; 38(11):825-31. PubMed ID: 11922940
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Heimberger AB; Crotty LE; Archer GE; Hess KR; Wikstrand CJ; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2003 Sep; 9(11):4247-54. PubMed ID: 14519652
[TBL] [Abstract][Full Text] [Related]
34. [Recent advance in carbohydrate-based cancer vaccines].
Huo CX; Ye XS
Yao Xue Xue Bao; 2012 Mar; 47(3):261-70. PubMed ID: 22645748
[TBL] [Abstract][Full Text] [Related]
35. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.
Huang YL; Hung JT; Cheung SK; Lee HY; Chu KC; Li ST; Lin YC; Ren CT; Cheng TJ; Hsu TL; Yu AL; Wu CY; Wong CH
Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2517-22. PubMed ID: 23355685
[TBL] [Abstract][Full Text] [Related]
36. Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1.
Perico ME; Mezzanzanica D; Luison E; Alberti P; Panza L; Russo G; Canevari S
Cancer Immunol Immunother; 2000 Aug; 49(6):296-304. PubMed ID: 10946811
[TBL] [Abstract][Full Text] [Related]
37. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines.
Grigalevicius S; Chierici S; Renaudet O; Lo-Man R; Dériaud E; Leclerc C; Dumy P
Bioconjug Chem; 2005; 16(5):1149-59. PubMed ID: 16173792
[TBL] [Abstract][Full Text] [Related]
38. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates.
Lo-Man R; Vichier-Guerre S; Perraut R; Dériaud E; Huteau V; BenMohamed L; Diop OM; Livingston PO; Bay S; Leclerc C
Cancer Res; 2004 Jul; 64(14):4987-94. PubMed ID: 15256473
[TBL] [Abstract][Full Text] [Related]
39. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Holmberg LA; Sandmaier BM
Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
